Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.

The user experienced significant hair regrowth using finasteride, minoxidil, and microneedling but later faced rapid thinning despite consistent treatment. They plan to switch from finasteride to dutasteride and consider oral minoxidil if the situation doesn't improve.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

A user started using RU58841 for hair loss and experienced anxiety and physical discomfort. Other users suggested avoiding the treatment due to similar side effects and recommended alternative treatments like pyri.

Topical melatonin may help reduce hair loss and increase hair thickness in people with androgenetic alopecia (AGA), with some studies showing positive results. It can be mixed with minoxidil for application, and its effectiveness might be enhanced when used with micro-needling, but results may vary among individuals.

The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.

Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

A user shared their 7-month progress using only topical finasteride for hair loss. They recently started a new, non-FDA treatment and will evaluate its effectiveness in 6 months.

The user is exploring hair loss treatments, including Patented Growth Factors (PGF) and a serum with Copper Peptide, Ceramides, Amino Acids, and Caffeine, while expressing concerns about the cost and effectiveness of PGF. They are also considering starting finasteride due to doubts about PGF's long-term viability and are seeking experiences from others who have used these treatments alongside antidepressants.

PP405 shows significantly better early-stage hair regrowth results compared to minoxidil and finasteride, with 31% of users experiencing over 20% density increase in 4–8 weeks. Minoxidil and finasteride show minimal or no visible regrowth in the same timeframe.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. Pyrilutamide Phase 2 results are expected in June 2022, with hopes for a better alternative to current treatments.

Peptides like GHK-Cu are discussed for hair regrowth, with mixed results; some users report no regrowth, while others notice thicker hair. Topical application is common, and proper sourcing and mixing are emphasized.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

The user is seeking alternatives to Minoxidil for hair growth, currently using 0.1% topical finasteride and 2% ketoconazole shampoo. Suggestions include microneedling, red light therapy, rosemary oil, and other topical treatments like cetirizine, Stemoxydine, and Latanoprost.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

People are hopeful about future hair loss treatments like PP405, GT20029, and VDPHL01, while some are currently using finasteride and minoxidil. There is skepticism about the effectiveness of new treatments, and some advise against hair transplants until more promising drugs are available.

Despite using treatments like Dutasteride, Minoxidil, RU58841, and GHK-Cu injections, the individual continues to experience aggressive hair thinning and is seeking a specialist for further help. Suggestions include trying finasteride, dermarolling, or another hair transplant.

The user is experiencing an allergic reaction to propylene glycol in Kirkland minoxidil and is considering switching to a foam version or a low-PG minoxidil solution. They are also contemplating oral minoxidil but are concerned about its long-term safety.

Koshine 826 (Pyrilutamide) is being used by several users to address hair loss, with mixed results on shedding and side effects. Some users report reduced shedding and no side effects, while others experience increased shedding and potential issues with libido and erectile dysfunction.

Topical sodium valproate may promote hair growth by inhibiting GSK3β, allowing beta-catenin to proliferate, but it has potential side effects and requires more research. The conversation also mentions skepticism about a product called Vdphlo1, which includes sodium valproate and other ingredients.

The user is using a combination of 7% minoxidil, 0.2% finasteride, 0.5mg finasteride, RU58841, and daily microneedling but is not seeing hair regrowth after 5 months. Suggestions include being patient, reducing microneedling frequency, considering oral minoxidil, and possibly switching to dutasteride if no improvement after a year.

Kintor is launching pyrilutamide as a cosmetic for hair loss. Users discuss its potential, comparing it to Cosmerna.

The conversation is about a person's hair loss treatment routine, which includes Metformin, sleep in darkness, avoiding EMF at night, Nizoral, Dermarolling, Castor oil, and Collagen. They have observed less hair shedding and increased hair volume.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The conversation discusses using B6 and Zinc to inhibit 5ar activity, similar to Fin and Dut. Minoxidil is mentioned as a supplementary treatment.

PG solvent is considered superior to K&B solvent for RU58841 and Pyralutamide due to cost and effectiveness. The user questions why they should use K&B when PG offers more benefits.

Hair loss discussion includes treatments like Minoxidil, finasteride, and RU58841. Platelet rich plasma treatment is considered expensive but cheaper than hair transplant.

The conversation discusses an interview with Dr. Tsuji about hair follicle stem cell multiplication and the financial challenges of starting human clinical trials. It also mentions the need for funding to secure a patent for a protein that promotes hair growth.

The conversation is about a user considering the use of Ketoconazole 2% shampoo before showing signs of male pattern baldness (MPB) to potentially delay its onset, inspired by a YouTuber who uses the shampoo to reduce scalp DHT levels. The user's interest in this preventative measure stems from a family history of MPB.

The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.